Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against... 
Sector
Biotechnology & Medical Research
Calendar
05/30 | 04:30pmShareholder meeting
More about the company
Latest news on CEL-SCI CORPORATION
05/24 CEL SCI : NEW STORY CEL-SCI Corporation Releases Letter to Shareholders
05/24 CEL-SCI CORPORATION : Releases Letter to Shareholders
05/18 CEL-SCI CORPORATION : Reports Second Quarter Fiscal Year 2017 Financial Results
05/16 CEL SCI : NEW STORY CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting
05/16 CEL SCI : Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting
05/12 CEL SCI CORP : Other Events (form 8-K)
05/12 CEL SCI : NEW STORY CEL-SCI Announces Change to the Date of Its Annual Meeting
05/12 CEL SCI : Announces Change to the Date of Its Annual Meeting
05/11 CEL SCI : Receives Intent to Grant Notice for New Multikine Patent from the Euro..
05/11 CEL SCI : Announces $1.51 Million Registered Direct Offering
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Geert R. Kersten CEO, CFO, Treasurer, Director & CAO
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION28
AMGEN, INC.5.74%112 531
CELGENE CORPORATION1.35%90 349
GILEAD SCIENCES, INC.-10.19%84 101
REGENERON PHARMACEUTIC..25.68%48 999
ACTELION LTD24.49%30 824
More Results